Many innovative medicines are in the pipeline. But new funding approaches will be needed to make sure there is a greater chance that they are brought to market. Dr. Neil Hayward is included as one of PharmaVOICE‘s 130 industry experts and was posed 20 provocative questions, focusing on how influencers think about aspirational goals in terms […]
For more than a decade we have been discussing the role that technology and nontraditional partners would play to move the industry toward a more efficient business model — one based more on health outcomes than product sales. Dr. Neil Hayward is included as one of PharmaVOICE‘s 130 industry experts and was posed 20 provocative questions, […]
As the wearable market continues to expand, the potential for smart clothing to monitor and manage health is breaking new ground. Dr. Neil Hayward is included as one of PharmaVOICE‘s 130 industry experts and was posed 20 provocative questions, focusing on how influencers think about aspirational goals in terms of health, what needs to happen to […]
The name of this company, eXIthera, refers to its therapeutic aim, inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants. Its lead drug, an injectable coded EP-7041, has completed a Phase 1 clinical trial in healthy human subjects and moved to a program in cardiac […]

Poster

Phase 1a/1b Study of EP-7041: A Novel, Potent, Selective, Small Molecule FXIa Inhibitor

Phase 1 results suggest the PK/PD profile of EP-7041 is ideal in acute care hospital settings where patients are at risk of thromboembolic events.

Download as PDF